Home › Ulcerative Colitis › Virginia › Roanoke
Ulcerative Colitis clinical trials in Roanoke, VA
4 studies for Ulcerative Colitis are looking for participants at sites in and around Roanoke (within about 30 miles). Open a study to see who can join and how to contact the study team.
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RecruitingPhase 3
- Gastroenterology Consultants of Southwest Virginia, Roanoke
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
RecruitingPhase 2
- Carilion Clinic, Roanoke
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RecruitingPhase 4
- Gastroenterology Consultants of Southwest Virginia., Roanoke
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RecruitingPhase 3
- Carilion Children's Tanglewood Center, Roanoke
About Ulcerative Colitis
Ulcerative Colitis (UC) can cause long-lasting swelling and ulcers in the large intestine. It is a type of inflammatory bowel disease. Find out more.
More about Ulcerative Colitis on MedlinePlus
Ulcerative Colitis trials in other cities
- New York City, NY24 studies
- Miami, FL22 studies
- Orlando, FL22 studies
- Houston, TX17 studies
- San Antonio, TX16 studies
- San Diego, CA15 studies
- Chicago, IL15 studies
- Tacoma, WA14 studies
- Colorado Springs, CO14 studies
- Tyler, TX13 studies
- Los Angeles, CA13 studies
- St. Louis, MO13 studies
Other studies in Roanoke
- Colorectal Cancer10 studies
- Heart Failure9 studies
- Non-Small Cell Lung Cancer8 studies
- Prostate Cancer7 studies
- Breast Cancer7 studies
- Metastatic Cancer6 studies
- Diabetic Foot5 studies
- Cancer (all types)4 studies
- Melanoma4 studies
- Stomach Cancer4 studies
- Small Cell Lung Cancer4 studies
- Crohn's Disease4 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.